A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Sponsor: Merck Sharp & Dohme LLC
Altamonte Springs, FL · Orlando, FL · West Palm Beach, FL · +36 more sites